Sari Alon

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial

Raphael Schiffmann, Özlem Göker-Alpan, Myrl Holida et al. · Journal of Inherited Metabolic Disease · 2019 · 133 citations · Full text

Immunogenicity of glycans on biotherapeutic drugs produced in plant expression systems—The taliglucerase alfa story

Bonita Rup, Sari Alon, Bat-Chen Amit-Cohen et al. · PLoS ONE · 2017 · 52 citations · Full text

Glycoproteomics, Protein Glycosylation, Engineering +15

Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study

Eric Wallace, Özlem Göker-Alpan, William R. Wilcox et al. · Journal of Medical Genetics · 2023 · 41 citations · Full text

Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study

Aleš Linhart, Gabriela Dostálová, Kathy Nicholls et al. · Orphanet Journal of Rare Diseases · 2023 · 29 citations · Full text

Long-term efficacy and safety results of taliglucerase alfa through 5 years in adult treatment-naïve patients with Gaucher disease

Ari Zimran, Gloria Durán, Pilar Giraldo et al. · Blood Cells Molecules and Diseases · 2016 · 27 citations · Full text